Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle PillsburyMarch 4, 2026
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success
Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…
CertaraMarch 3, 2026
On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
CertaraFebruary 26, 2026
From Documentation to Design: Building a Scalable Metadata Strategy for Clinical Research
Learn how clinical teams are treating metadata as infrastructure to improve reuse, auditability, and standards…
CertaraFebruary 26, 2026
Metatdata as Infrastructure: Designing for Reuse, Insight, and Auditability
Watch this on-demand webinar to learn how leading clinical teams design scalable metadata strategies that…
CertaraFebruary 26, 2026
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success
Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…
CertaraFebruary 23, 2026
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development
Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…
CertaraFebruary 18, 2026
Pediatric Drug Development: From “Wild West” to Model-Informed Confidence
Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…
CertaraFebruary 11, 2026
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…
CertaraFebruary 2, 2026
